DianeVHavlirMD

Infectious Disease • San Francisco, CA

Professor, Medicine, University of California, San Francisco, School of Medicine

Join to view full profile

Are you Dr. Havlir?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 37 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
995 Potrero Ave
Bldg 80 Ward 84
San Francisco, CA 94110
Phone+1 415-476-4082

Fax+1 415-502-2992

Summary

Dr. Diane Havlir, MD is an infectious disease specialist in San Francisco, California. She is currently licensed to practice medicine in California and Ohio. She is affiliated with Zuckerberg San Francisco General Hospital and Trauma Center and is a Professor at University of California.

Education & Training

Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Infectious Disease, 1988 - 1990
University of California (San Francisco)Internship, Internal Medicine, 1984 - 1985
Duke University School of MedicineClass of 1984

Certifications & Licensure

CA State Medical License 1986 - 2025
OH State Medical License 1988 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 2004

Clinical Trials

A Study to Monitor Patients With Primary or Early HIV Infection Start of enrollment: 1999 Oct 01
Completed
Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals
Withdrawn
Not Applicable
A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly
Completed
Phase 2
Observing Patients With Early HIV Infection
Completed
Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV Treatment
Withdrawn
Phase 3
Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care
Completed
Phase 3
Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis Start of enrollment: 2004 Oct 01
Completed
Phase 3
Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis Start of enrollment: 2006 Aug 01
Completed
Phase 4
Relationship Between HIV and Malaria in Ugandan Children Start of enrollment: 2005 Nov 01
Completed
Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut Start of enrollment: 2008 Sep 01
Completed
Not Applicable
Chemopreventive Therapy for Malaria in Ugandan Children Start of enrollment: 2010 Jun 01
Completed
Phase 3
HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children Start of enrollment: 2009 Sep 01
Completed
Phase 3
Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women Start of enrollment: 2009 Dec 15
Completed
Phase 3
Early HIV Therapy in Patients With High CD4 Cell Counts Start of enrollment: 2011 Oct 01
Completed
Not Applicable
Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects Start of enrollment: 2012 May 01
Completed
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir Start of enrollment: 2013 Apr 25
Completed
Phase 4
The "START" (a Streamlined ART Initiation Strategy) Study Start of enrollment: 2013 Apr 01
Completed
Not Applicable
Sustainable East Africa Research in Community Health Start of enrollment: 2013 Apr 01
Completed
Not Applicable
Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery Start of enrollment: 2014 Jul 02
Completed
Phase 2
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection Start of enrollment: 2014 May 30
Completed
Phase 1
Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants Start of enrollment: 2014 Jun 23
Completed
Phase 3
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART) Start of enrollment: 2015 Dec 21
Completed
Phase 1, Phase 2
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants Start of enrollment: 2016 Sep 01
Completed
Phase 3
Biomarkers to Predict Time to Plasma HIV RNA Rebound Start of enrollment: 2017 Feb 23
Completed
PREPARE (A5361s) Substudy of REPRIEVE (A5332) Start of enrollment: 2017 Feb 28
Completed
Simplified Isoniazid Preventive Therapy Strategy to Reduce TB Burden Start of enrollment: 2017 Nov 15
Completed
Not Applicable
Strategic Antiretroviral Therapy and HIV Testing for Youth in Rural Africa Start of enrollment: 2019 Mar 14
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

43 citations
Sex differences in HIV RNA level and CD4 cell percentage during childhood.
Theodore Ruel, Brian C. Zanoni, Isaac Ssewanyana, Huyen Cao, Diane V. Havlir
Clinical Infectious Diseases. 2011-09-15
15 citations
HIV post-treatment controllers have distinct immunological and virological features.
Behzad Etemad, Xiaoming Sun, Yijia Li, Meghan Melberg, Daniela Moisi
Proceedings of the National Academy of Sciences of the United States of America. 2023-03-14
236 citations
Differences in HIV Burden and Immune Activation within the Gut of HIV-Positive Patients Receiving Suppressive Antiretroviral Therapy
Steven A. Yukl, Sara Gianella, Elizabeth Sinclair, Lorrie Epling, Qingsheng Li
The Journal of Infectious Diseases. 2010-11-15

Press Mentions

A Blueprint for More Equitable Care in Public Health CrisesDecember 7th, 2022
Breakthrough COVID Research. Vital Health Care for Locals. And Now It Risks ClosureOctober 15th, 2022
Covid-19 Tracker: On Another PlateauJune 1st, 2022
Join now to see all

Grant Support

UCSF HIV Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2007–2012
Therapeutic Strategies For HIV DiseaseNational Institute Of Allergy And Infectious Diseases2002–2012
Protease Inhibitors To Reduce Malaria In Hiv-Infected Pregnant WomenEunice Kennedy Shriver National Institute Of Child Health &Human Development2008–2011
Novel Strategies To Prevent Malaria And Improve HIV Outcomes In AfricaEunice Kennedy Shriver National Institute Of Child Health &Human Development2008–2011
Core A. AdministrativeEunice Kennedy Shriver National Institute Of Child Health &Human Development2008–2011
Training In HIV Translational ResearchNational Institute Of Allergy And Infectious Diseases2005–2011
Pepfar - Streamlining Care In High CD4, HIV+ Adults In AfricaNational Institute Of Allergy And Infectious Diseases2010
Protease Inhibitors To Reduce Malaria In Hiv-Infected Pregnant WomenEunice Kennedy Shriver National Institute Of Child Health &Human Development2010
Core A: AdministrativeEunice Kennedy Shriver National Institute Of Child Health &Human Development2010
Clinical Studies Of Interactions Between HIV And MalariaNational Institute Of Allergy And Infectious Diseases2004–2008
Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2002–2006
Therapeutic Strategies For HIV DiseaseNational Institute Of Allergy And Infectious Diseases2002
SAN Diego AIDS Clinical Trial UnitNational Institute Of Allergy And Infectious Diseases2000–2001
Core--Clinical InvestigationNational Institute Of Allergy And Infectious Diseases1998–2001
Phase I Study Of Navin In HIV Infected PatientsNational Center For Research Resources1996
Cctg552 Mycobacterium Avium And Fungal Infection In HIVNational Center For Research Resources1996
The T Cell Response To Mycobacterial Infection In AIDS PatientsNational Institute Of Allergy And Infectious Diseases1994–1995